ClinicalTrials.gg
CompletedNCT01485146Updated Mar 28, 2019

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

A Phase 1 interventional study of ETC-1002 in Safety Evaluation of Escalating Doses, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-28.

Sponsored by Esperion Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.

02

Conditions studied

  • Safety Evaluation of Escalating Doses
03

In context

Lead sponsor

Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Major Inclusion Criteria:

  • Healthy male and female subjects of non-child bearing potential as determined by medical history, physical exam and vial sign measurements
  • of 18-32 kg/m2 inclusive with body weight >50 kg

Major Exclusion Criteria:

  • (ALT) or aspartate aminotransferase (AST) >1.2 x (ULN), serum creatinine >ULN, \<12.0 g/dL
  • disease that requires a physician's care and/or would interfere with study evaluations
  • History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to randomization, or a positive test for alcohol or drugs with a high potential for abuse prior to randomization
  • Use of any prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to randomization
  • Other exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1

    8 Healthy Subjects in Phase I Unit

    Drug: ETC-1002

  • Experimental
    Cohort 2

    8 Healthy Subjects in Phase I Unit

    Drug: ETC-1002

  • Experimental
    Cohort 3

    8 Healthy Subjects in Phase I Unit

    Drug: ETC-1002

Interventions

06

What researchers measure

Primary outcomes

  1. Measuring subject safety by collecting and evaluating vital signs, adverse events, and laboratory measures.

    Time frame: 14 days

Secondary outcomes

  1. Measuring the level of ETC-1002 and its metabolite ESP15228 in the blood.

    Time frame: 14 days

07

Study locations

1 site
  • Jasper Clinic, Inc.
    Kalamazoo, Michigan 49007, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Jan 2012, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2011
First posted
Dec 5, 2011
StartActual
Oct 25, 2011
Primary completionActual
Jan 25, 2012
CompletionActual
Jan 25, 2012
Last update
Mar 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01485146
Responsible party
Sponsor
First posted
Dec 5, 2011
Start date
Oct 25, 2011
Primary completion
Jan 25, 2012
Completion
Jan 25, 2012
Last update
Mar 28, 2019

Study contacts

Narendra Lalwani, PhD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion